Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2008

View Archived Issues

LOR-253 induces cancer cell cycle arrest in preclinical studies

CK2 protein kinase inhibitor shows antitumor activity in preclinical studies

Novartis rounds up Q1 developments

DEBIO-025 enhances antiviral effect of pegylated interferon alpha-2a in HCV patients

PF-03732010 active in vivo against P-cadherin-expressing cancers

Small-molecule inhibitors of Cdc7 kinase developed at Nerviano Medical Sciences

Progen reports synthesis of novel heparan sulfate mimetics

Alexza completes enrollment in phase IIa AZ-002 trial in panic disorder

Cleveland BioLabs presents update on the company's 2008 activities

ImmuneRegen to supply adjuvant to DynPort for Venezuelan equine encephalitis vaccine

Critical Therapeutics signs merger agreement with Cornerstone BioPharma

Accentia reports results from pivotal phase III trial of SinuNase for chronic sinusitis

3M and Infectious Disease Research Institute collaborate on vaccine adjuvants

Sepracor acquires Oryx and expands commercial operations into Canada

Sepracor and Arrow sign agreement to enhance ciclesonide and Brovana

Discovery Labs receives FDA approvable letter for Surfaxin

Oncothyreon files IND with the FDA for PX-866 for advanced cancers

Pro-Pharmaceuticals updates NDA filing plan for Davanat

AstraZeneca files marketing application for Iressa in Europe

Mologen receives approval for phase I MGN-1703 clinical study in cancer

Renovis stockholders approve adoption of the merger agreement with Evotec

New agents for treating neurological disorders disclosed in recent patent literature

Novel antithrombotic agents reported in recent patents

Recent Synta patent reports novel immunosuppressant agents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...